Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) DMX-652 offers potential to address a significant unmet need in AKI - with a global market opportunity estimated to be US$3.5 billion in 2026,[1] and no currently approved therapies for the disease which is associated with rapid decline in kidney function and high mortality r

Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies including Johnson & Johnson. AtaiBeckley’s lead candidate is BPL-003, a fast-acting intranasal formulation of the psychedelic substance 5-MeO-DMT. The substance, which is found in some plants and animals, stimulates the serotonin system that regulates mood. A phase 2b trial linked BPL-003 to statistically significant improve

Spero Therapeutics is putting over $1 billion on the line in exchange for rights to develop SP001, an anti-CD40L antibody, for IgG4-related disease. A Phase 2 study is planned for the second quarter of 2027. Spero Therapeutics has licensed an investigational autoimmune disease therapy from China-based Innovent Biologics. The total deal value could reach up to $1.1 billion, according to a Tuesday morning news release. This sum includes Spero’s upfront commitment, as well as R&D, regulatory and

Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. July 13, 2026 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise The

GSK reported positive data Friday from a B7-H3-targeting asset partnered with Hansoh Pharmaceutical Group Co. The Phase III ARTEMIS-008 trial run in China is testing the antibody-drug conjugate (ADC) risvutatug rezetecan (ris-rez) and has succeeded on its primary endpoint of overall survival (OS) in patients with advanced or relapsed small-cell lung cancer (SCLC), the UK drugmaker said. Hansoh will use the results to back its request for regulatory approval in China. GSK acquired ex-China righ

—Cooperative Research and Development Agreement (CRADA) will utilize Apertura's TfR1 CapX™ Capsid— —Ara Parseghian Medical Research Fund, a non-profit organization dedicated to finding a treatment or cure for Niemann-Pick Type C, will contribute financial support to the research— July 9, 2026 -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced that it has entered into a Cooperative Research and Development Ag

In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered symptom burden in patients with chronic obstructive pulmonary disorder. AstraZeneca has gone on another excursion to Asia, this time enlisting Sino Biopharmaceutical for a global licensing deal to address a chronic respiratory disorder. The pharma is paying $200 million upfront and offering up to $1.9

Vertex Pharmaceuticals is making the largest acquisition bet in its history, announcing late Monday an agreement to purchase a biotechnology company, Crinetics Pharmaceuticals, that recently brought to market a new kind of medicine for a rare hormonal disorder. Vertex is paying $85 per share in cash, or $10 billion overall, for Crinetics. The deal ranks as the fourth largest, by total proceeds, in an already busy year for biotech company acquisitions, according to BioPharma Dive data. Additiona

July 7, 2026 -- Helix, the leading enterprise genomics company, today announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under this agreement AstraZeneca will gain access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas. GenoSphere cohorts consist of comprehensive Exome+® genomic and rich longitudinal clinical data, designed to accelerate Life Sciences research across the development cycle. The

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas July 1, 2026 -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas. The collaboration is designed to identify clinically differentiated drug candidates for pr